- All Journals
- Al-Qadisiyah University
- Basrah University
- Kirkuk University
- Mosul University
- The Iraqi Borad for Medical Specialization
- University of Anbar
- University of Technology
- Al Mustafa University
- Al-Zahraa University for Women
- Alnoor University
- Kunooz University
- Misan University
- Ninevah University
- Tikrit University
- University of Al-Hamdaniya
- University of Kerbala
Detection of Pan Braf in Thyroid Tumors in Iraqi Patients | ||
| Iraqi Journal of Science | ||
| Article 1, Volume 58, Issue 4, 2018, Pages 1820-1828 | ||
| Author | ||
| Ban Jasim Mohamad | ||
| Abstract | ||
| The B-type Raf kinase (BRAF) is a member of RASRAFMEKERK pathway and this pathway can lead to increased cellular growth, invasion and metastasis. The mutated BRAF protein activates MAPK signaling pathway, results in abnormal cellular growth, apoptosis resistance, tumor progression and metastasis. Pan-BRAF is one of available BRAF monoclonal antibodies and shared by both the wild and mutant BRAF.BRAF status is mostly determined by DNA sequencing methods. In this investigation we assessed the monoclonal Pan BRAF specific antibody that can identify wild and mutant type proteins together in formalin-fixed paraffin-embedded thyroid tumor tissues by Immunohistochemistry (IHC). Archival thyroid samples from 43 iraqi patients were immunohistochemically tested with antibodies for BRAF. Out of 43 thyroid tissue cases, (23) were thyroid malignant,(12) benign, and (8) control cases(diagnosed as colloid goiter).The malignant tumors included Papillary Thyroid Carcinoma (PTC), Follicular Thyroid Carcinoma (FTC), Medullary Thyroid Carcinoma (MTC), Anaplastic Thyroid Carcinoma (ATC) and Hürthle cell cancer (HCC).Immunohistochemical staining for BRAF was performed for all specimens. Results of the study showed that Immunohistochemical expression of pan BRAF was significantly higher in malignant thyroid tumors as compared with adenomas and control cases (P<0.05). BRAF over-expression was detected in 512 of PTC, 35 MTC, 24 of FTCas well as all cases of HCC, ATC.Whereas it was detected in 412 of adenomas, and totally negative in control cases. No association was observed between BRAF and other clinicopathological traits. We conclude from this study that IHC using BRAF monoclonal antibody is a successful way for checking of BRAF status in different thyroid tumors. IHC may be the alternative to molecular biology for the routine detection of this marker in patients with thyroid tumors. | ||
| Keywords | ||
| BRAF Monoclonal antibodies; Immunohistochemistry; Thyroid Carcinoma | ||
|
Statistics Article View: 151 PDF Download: 111 |
||